Benzinga.com

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

AC Immune SA (NASDAQ:ACIU) revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease. Dr. Andrea Pfeifer ...

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate UpdatePhase 2 interim results suggest treatment with active ...
Seeking Alpha

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune (ACIU) to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the ...
Business Wire

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

− Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression − AC Immune to ...
Nasdaq

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations 100% of patients receiving ACI-7104.056 responded ...
Nasdaq

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high ...